In Vitro and In Vivo Efficacy and Tolerability of a Non-Hydroquinone, Multi-Action Skin Tone Correcting Cream
July 2019 | Volume 18 | Issue 7 | Original Article | 642 | Copyright © July 2019
Pearl E. Grimes MD,a David H. McDaniel MD,b Mitchell Wortzman PhD,c Diane Nelson RN MPHc
aVitiligo & Pigmentation Institute of Southern California, Los Angeles, CA
bMcDaniel Institute of Anti-Aging Research, Virginia Beach, VA
cskinbetter science LLC, Phoenix, AZ
the overall quality of skin. This new, non-hydroquinone skin
tone correcting cream represents an effective, non-irritating
treatment option for patients with photodamage seeking to
reduce the appearance of hyperpigmentation and improve the
overall quality of their skin.
Pearl E. Grimes, MD: Director, Vitiligo and Pigmentation Institute
of Southern California; Division of Dermatology, David Geffen
School of Medicine, UCLA, Los Angeles, CA: Investigator for
skinbetter science. David H. McDaniel, MD: Director, McDaniel
Institute of Anti-Aging Research and McDaniel Laser and Cosmetic
Center; Co-Director, Hampton University Skin of Color
Research Institute, Hampton, VA; Adjunct Professor, School of
Science, Hampton University, Hampton, VA; Adjunct Assistant
Professor, Old Dominion University, Department of Biological
Sciences, Norfolk, VA: Investigator and Consultant for skinbetter
science. Mitchell Wortzman, PhD: Employee of skinbetter science.
Diane B. Nelson, RN, MPH: Employee of skinbetter science.
We would like to thank Lynne Kolton Schneider, PhD, for her
editorial assistance on this manuscript.
- Kang SJ, Davis SA, Feldman SR, McMichael AJ. Dyschromia in skin of color. J Drugs Dermatol. 2014;13(4):401-406.
- Vashi NA, Kundu RV. Facial hyperpigmentation: causes and treatment. Br J Dermatol. 2013;169 Suppl 3:41-56.
- Konda S, Geria AN, Halder RM. New horizons in treating disorders of hyperpigmentation in skin of color. Semin Cutan Med Surg. 2012;31(2):133-139.
- Abe Y, Takabe W, Yagi M, et al. Melanin synthesis induction by advanced glycation end-products (AGEs) without α-melanocyte stimulating hormone (α-MSH) or UV exposure. Glycative Stres Res. 2016;3(4):229-235.
- Barsh GS. What controls variation in human skin color? PLoS Biology. 2003;1(1):e27.
- Bastonini E, Kovacs D, Picardo M. Skin pigmentation and pigmentary disorders: focus on epidermal/dermal cross-talk. Ann Dermatol. 2016;28(3):279- 289;
- D’Mello SA, Finlay GJ, Baguley BC, Askarian-Amiri ME. Signaling pathways in melanogenesis. Int J Mol Sci. 2016;17(7).
- Videira IFdS, Magina S, Moura DFL. Mechanisms regulating melanogenesis. An Bras Dermatol. 2013;88(1):76-83.
- Kolbe L, Mann T, Gerwat W, et al. 4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation. J Eur Acad Dermatol Venereol. 2013;27 Suppl 1:19-23.
- Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20-31.
- Plensdorf S, Martinez J. Common pigmentation disorders. Am Fam Physician. 2009;79(2):109-116.
- Guerrero D. Dermocosmetic management of hyperpigmentations. Ann Dermatol Venereol. 2012;139 Suppl 4:S166-S169.
- Woolery-Lloyd H, Kammer JN. Treatment of hyperpigmentation. Semin Cutan Med Surg. 2011;30(3):171-175.
- Halder RM, Richards GM. Topical agents used in the management of hyperpigmentation. Skin Ther Lett. 2004;9(6):1-3.
- Sofen B, Prado G, Emer J. Melasma and post inflammatory hyperpigmentation: Management update and expert opinion. Skin Therapy Lett. 2016;21(1):1-7.
- Inoue Y, Hasegawa S, Yamada T, et al. Analysis of the effects of hydroquinone and arbutin on the differentiation of melanocytes. Biol Pharm Bull. 2013
- McDaniel DH, Mazur C, Wortzman MS, Nelson DB. Efficacy and tolerability of a double-conjugated retinoid cream vs 1.0% retinol cream or 0.025% tretinoin cream in subjects with mild to severe photoaging. J Cosmet Dermatol. 2017 Dec;16(4):542-548.
- Thornfeldt C, Rizer RL, Trookman NS. Blockade of melanin synthesis, activation and distribution pathway by a nonprescription natural regimen is equally effective to a multiple prescription-based therapeutic regimen. J Drugs Dermatol. 2013;12(12):1448-1454.
- Grimes PE. An efficacy study of 3 commercially available hydroquinone 4% treatments for melasma. Cutis. 2007;80:497-502.
- Draelos ZD, Yatskayer M, Bhushan P, Pillai S, Oresajo C. Evaluation of a kojic acid, emblica extract, and glycolic acid formulation compared with hydroquinone 4% for skin lightening. Cutis. 2010;86(3):153-158.
- Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007;20(5):308-313.
- Fisk WA, Agbai O, Lev-Tov HA, Sivamani RK. The use of botanically derived agents for hyperpigmentation: a systematic review. J Am Acad Dermatol. 2014;70(2):352-365.
- Bruce S. Safety and efficacy of a novel multimodality hydroquinone-free skin brightener over six months. J Drugs Dermatol. 2013;12(3):S27-S31.
- Fabi SG, Goldman MP. Comparative study of hydroquinone-free and hydroquinone-based hyperpigmentation regimens in treating facial hyperpigmentation and photoaging. J Drugs Dermatol. 2013;12(3):S32-S37.
- Farris P, Zeichner J, Berson D. Efficacy and tolerability of a skin brightening/ anti-aging cosmeceutical containing retinol 0.5%, niacinamide, hexylresorcinol, and resveratrol. J Drugs Dermatol. 2016;15(7):863-868.
- Foad MS, Winters E. Hydroquinone-free multimodal topical regimen for facial hyperpigmentation. J Drugs Dermatol. 2013;12(3 Suppl 1):S42-S44.
- Gold MH, Biron J. Efficacy of a novel hydroquinone-free skin-brightening cream in patients with melasma. J Cosmet Dermatol. 2011;10(3):187-196.
- Jung YS, Lee JH, Bae JM, Lee DW, Kim GM. Assessment of the efficacy and safety of a new complex skin cream in Asian women: a controlled clinical trial. J Cosmet Dermatol. 2017;16(2):253-257